Profile

Cover photo
Verified local business
Conversant Biologics, Inc.
Biotechnology Company
Today Closed
23 followers|33,961 views
AboutPostsPhotosYouTube
Contact Information
Map of the business location
601 Genome Way Northwest Huntsville, AL 35806
601 Genome Way NorthwestUSAlabamaHuntsville35806
(866) 838-2798conversantbio.com
Biotechnology CompanyToday Closed
Saturday ClosedSunday ClosedMonday 8AM–5PMTuesday 8AM–5PMWednesday 8AM–5PMThursday 8AM–5PMFriday 8AM–5PM

Conversant Bio was founded in 2006 because the drug discovery research model was broken.

It simply takes too long for drugs to get to patients, there are too many failures late in development, and the entire process costs too much. The lack of well-characterized, appropriately consented human biospecimens continues to hamper the development of new drugs.  Seeking to fix this process, Conversant Bio addresses these problems in a new way. 

From day one,  we’ve had one mantra guide us:Because Patients Are Waiting… ™


Google+ URL

Street View

Panorama
Your Activity
Write a review
Review Summary
Be the first to review
Photos
Scrapbook photo 2
Scrapbook photo 3
Scrapbook photo 4
Upload public photo
People
Have them in circles
23 people
HEALthCast's profile photo
Analyn Bengs's profile photo
Covance's profile photo
Dr.Stacy Gyles's profile photo
Biotech 365's profile photo
Cristina Cercel's profile photo
lindy lorel's profile photo
Abdul haris's profile photo
Biomarker Profiles's profile photo

Stream

 
Our newest infographic about cancer staging: the TNM System. Do you use the TNM system in your oncology research?
1
Add a comment...
 
Colorectal cancer (CRC) is one of the most challenging forms of cancer to successfully treat, mainly because of the high heterogeneity of CRC tumors. Yet, finding effective therapies is essential because CRC is the second leading cause of death worldwide in the western world.

http://hubs.ly/H01nnGq0
There is a great deal of research going on to better understand how CRC tumor genetic differences are associated with differing clinical outcomes.
1
Add a comment...
 
Glad to be here because patients are waiting!
601 Genome Way Northwest, Huntsville, AL 35806
1
Add a comment...
 
Conversant Bio is proud to assist the top US and global biopharmas with human biospecimen procurement. We have high-quality diseased and normal patient blood and FFPE for:

- genomic and proteomic biomarker discovery
- target verification
- assay development and performance characteristics
- positive and negative real patient controls
- validation panel development
- access to thousands of unique patient cases
- full chain of custody ensures uniformity and quality of pre-analytical variables

Learn more about our characterized mutation FFPE by viewing this short presentation.

http://hubs.ly/H01d76t0 
1
Add a comment...
 
Lead study author, Hans-Christian Kolberg, MD of Marien Hospital Bottrop in Bottrop, Germany, discusses the updated results and the impact they may have on the treatment paradigm for HER2-positive breast cancer.

http://hubs.ly/H01jwZB0
1
Add a comment...
Have them in circles
23 people
HEALthCast's profile photo
Analyn Bengs's profile photo
Covance's profile photo
Dr.Stacy Gyles's profile photo
Biotech 365's profile photo
Cristina Cercel's profile photo
lindy lorel's profile photo
Abdul haris's profile photo
Biomarker Profiles's profile photo
 
Did you know the early stages of colorectal cancer often exhibits minimal or no symptoms? Conversant Bio is glad to be assisting researchers in developing new diagnostic tools because patients are waiting.

http://hubs.ly/H02771M0
There are many advancements in diagnostic and treatment regimens for metastatic colorectal cancer that are leading to improved quality of life.
1
Add a comment...
 
We are pleased to announce the launch of a new FFPE product. To learn more about how Conversant Bio can help your team, visit us: http://hubs.ly/H01mp6Q0
1
Add a comment...
 
How Does Histologic Subtype Influence Metastatic Patterns in Colorectal Cancer? http://hubs.ly/H01pQyq0
Here is a review of five histologic subtypes in colorectal cancer.
1
Add a comment...
 
Looking forward to this new source of great information about our industry.

The goal, Henry says, is to be "the country's go-to news source for the life sciences."
Red Sox and Boston Globe owner John Henry launches an ambitious digital news outlet for health reporting.
1
Add a comment...
 
[Infographic] How will more personalized therapeutics make a difference in creating better patient outcomes? http://hubs.ly/H01jY-n0 
Bayer HealthCare Pharmaceuticals is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer HealthCare Pharmaceuticals aims for leading positions in specialized markets worldwide. Using new ideas, Bayer HealthCare Pharmaceuticals a...
1
Add a comment...
 
Interesting article from a second year med student on his experiences with metastatic breast cancer survivors.

Metastatic Breast Cancer: A Student’s Perspective http://hubs.ly/H01jZ410
Recently I had the privilege of attending “A Journey of Courage and Hope: The Johns Hopkins Metastatic Breast Cancer Retreat for Couples.” Facilitated by a renowned leader in patient-centered breast cancer care, Lillie Shockney, this unique retreat for patients and their spouses explores the ...
1
Add a comment...
 
Information about RAS mutations plays a key role in advancing new therapies and diagnostics for patients with cancer. AACR recently released a collection of molecular cancer research papers focussing on RAS mutations. Here are a few short summaries of 4 of those papers.

http://hubs.ly/H01hh4v0
Here we summarize the remaining four articles from the recently published RAS research collection of Molecular Cancer Research.
1
Add a comment...